Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2008 1
2013 2
2014 1
2015 3
2016 3
2017 5
2018 7
2019 6
2020 5
2021 6
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean brain turpin[Author] (103 results)?
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Drilon A, et al. Among authors: turpin b. N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448. N Engl J Med. 2018. PMID: 29466156 Free PMC article. Clinical Trial.
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS. Laetsch TW, et al. Among authors: turpin b. Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29. Lancet Oncol. 2018. PMID: 29606586 Free PMC article. Clinical Trial.
Immuno-transcriptomic profiling of extracranial pediatric solid malignancies.
Brohl AS, Sindiri S, Wei JS, Milewski D, Chou HC, Song YK, Wen X, Kumar J, Reardon HV, Mudunuri US, Collins JR, Nagaraj S, Gangalapudi V, Tyagi M, Zhu YJ, Masih KE, Yohe ME, Shern JF, Qi Y, Guha U, Catchpoole D, Orentas RJ, Kuznetsov IB, Llosa NJ, Ligon JA, Turpin BK, Leino DG, Iwata S, Andrulis IL, Wunder JS, Toledo SRC, Meltzer PS, Lau C, Teicher BA, Magnan H, Ladanyi M, Khan J. Brohl AS, et al. Among authors: turpin bk. Cell Rep. 2021 Nov 23;37(8):110047. doi: 10.1016/j.celrep.2021.110047. Cell Rep. 2021. PMID: 34818552 Free PMC article.
A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.
Moreno L, Teira P, Croop JM, Gerber NU, André N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA. Moreno L, et al. Among authors: turpin b. Front Pediatr. 2023 May 24;11:1183295. doi: 10.3389/fped.2023.1183295. eCollection 2023. Front Pediatr. 2023. PMID: 37292376 Free PMC article.
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force.
Pacenta HL, Allen-Rhoades W, Langenau D, Houghton PJ, Keller C, Heske CM, Deel MD, Linardic CM, Shern JF, Stewart E, Turpin B, Harrison DJ, Khan J, Mascarenhas L, Skapek SX, Meyer WH, Hawkins DS, Chen EY, Amatruda JF, Hingorani P, Laetsch TW. Pacenta HL, et al. Among authors: turpin b. J Clin Med. 2021 Apr 1;10(7):1416. doi: 10.3390/jcm10071416. J Clin Med. 2021. PMID: 33915882 Free PMC article. Review.
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D, Shukla S, Gryder BE, Pradhan A, Donovan J, Sudha P, Vallabh S, Pyros A, Xu Y, Barski A, Szabo S, Turpin B, Pressey JG, Millay DP, Khan J, Kalinichenko VV, Kalin TV. Milewski D, et al. Among authors: turpin b. Oncogene. 2021 Mar;40(12):2182-2199. doi: 10.1038/s41388-021-01694-9. Epub 2021 Feb 24. Oncogene. 2021. PMID: 33627785 Free PMC article.
ASO Author Reflections: Minimizing Time in Hospital via Bone Biopsy or Other Means.
Cooke-Barber J, Brungardt JG, Sorger M, Pressey JG, Turpin B, Nagarajan R, Szabo S, Sorger J, Johnson N, Dasgupta R. Cooke-Barber J, et al. Among authors: turpin b. Ann Surg Oncol. 2023 Jun;30(6):3666. doi: 10.1245/s10434-023-13170-7. Epub 2023 Feb 18. Ann Surg Oncol. 2023. PMID: 36808591 No abstract available.
Identification of NTRK fusions in pediatric mesenchymal tumors.
Pavlick D, Schrock AB, Malicki D, Stephens PJ, Kuo DJ, Ahn H, Turpin B, Allen JM, Rosenzweig M, Badizadegan K, Ross JS, Miller VA, Wong V, Ali SM. Pavlick D, et al. Among authors: turpin b. Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26433. Epub 2017 Jan 18. Pediatr Blood Cancer. 2017. PMID: 28097808
Undifferentiated myxoid lipoblastoma with PLAG1-HAS2 fusion in an infant; morphologically mimicking primitive myxoid mesenchymal tumor of infancy (PMMTI)--diagnostic importance of cytogenetic and molecular testing and literature review.
Warren M, Turpin BK, Mark M, Smolarek TA, Li X. Warren M, et al. Among authors: turpin bk. Cancer Genet. 2016 Jan-Feb;209(1-2):21-9. doi: 10.1016/j.cancergen.2015.11.004. Epub 2015 Nov 18. Cancer Genet. 2016. PMID: 26701195 Review.
44 results